The Data and Safety Monitoring Committee (DSMC) of the NYU Cancer Institute (NYUCI) operates based on the Data and Safety Monitoring Plan approved by the NCI in November 2011 and the highest priority is placed on ensuring the safety of patients who enroll on clinical trials. The DSMC is a multidisciplinary committee composed of clinical investigators, biostatisticians and research administrative staff from the Clinical Trials Office (CTO), all with expertise in research methodology and the conduct of clinical trials. The DSMC reports to the Director of the NYUCI (WilHam L. Carroll, MD). The DSMC oversees the conduct of institutional trials. In addition, the NYUCI Internal Audit Committee and Phase I/II Committee review all Investigator-Initiated trials or Multi-Center Trials which NYUCI is the coordinating center. The lAC is a quality assurance mechanism to assess compliance with protocol procedures and data integrity, FDA regulations and CTO policy. Phase I/II Committee provides a mechanism to more closely monitor accrual, timeliness of data collections, adverse events and the available resources needed to achieve study endpoints.

Public Health Relevance

The DSMC is responsible for monitoring safety, conduct and compliance with protocol data monitoring plans for clinical trials conducted within the NYUCI that are not monitored by any other institution or agency.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016087-33
Application #
8436456
Study Section
Subcommittee G - Education (NCI)
Project Start
2013-03-01
Project End
2018-02-28
Budget Start
2013-04-01
Budget End
2014-02-28
Support Year
33
Fiscal Year
2013
Total Cost
$28,531
Indirect Cost
$11,698
Name
New York University
Department
Type
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Huang, Chao; Zeng, Xingruo; Jiang, Guosong et al. (2017) XIAP BIR domain suppresses miR-200a expression and subsequently promotes EGFR protein translation and anchorage-independent growth of bladder cancer cell. J Hematol Oncol 10:6
Silvera, Deborah; Ernlund, Amanda; Arju, Rezina et al. (2017) mTORC1 and -2 Coordinate Transcriptional and Translational Reprogramming in Resistance to DNA Damage and Replicative Stress in Breast Cancer Cells. Mol Cell Biol 37:
Koh, Hyunwook; Blaser, Martin J; Li, Huilin (2017) A powerful microbiome-based association test and a microbial taxa discovery framework for comprehensive association mapping. Microbiome 5:45
Ma, Lijie; Liu, Yan; Landry, Nichole K et al. (2017) Point mutation in D8C domain of Tamm-Horsfall protein/uromodulin in transgenic mice causes progressive renal damage and hyperuricemia. PLoS One 12:e0186769
Morabito, Michael V; Ravussin, Yann; Mueller, Bridget R et al. (2017) Weight Perturbation Alters Leptin Signal Transduction in a Region-Specific Manner throughout the Brain. PLoS One 12:e0168226
Koetz-Ploch, Lisa; Hanniford, Douglas; Dolgalev, Igor et al. (2017) MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. Pigment Cell Melanoma Res 30:328-338
Feig, Jessica L; Mediero, Aranzazu; Corciulo, Carmen et al. (2017) The antiviral drug tenofovir, an inhibitor of Pannexin-1-mediated ATP release, prevents liver and skin fibrosis by downregulating adenosine levels in the liver and skin. PLoS One 12:e0188135
Ono, Kentaro; Viet, Chi T; Ye, Yi et al. (2017) Cutaneous pigmentation modulates skin sensitivity via tyrosinase-dependent dopaminergic signalling. Sci Rep 7:9181
Wang, Xing; Zhang, Fenglin; Wu, Xue-Ru (2017) Inhibition of Pyruvate Kinase M2 Markedly Reduces Chemoresistance of Advanced Bladder Cancer to Cisplatin. Sci Rep 7:45983
Garré, Juan Mauricio; Silva, Hernandez Moura; Lafaille, Juan J et al. (2017) CX3CR1+ monocytes modulate learning and learning-dependent dendritic spine remodeling via TNF-?. Nat Med 23:714-722

Showing the most recent 10 out of 1082 publications